You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Autism Treatment The Pivotal Skills Trainer

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR (Phase 1) project begins the translation of untapped scientific findings into an improved software tool for teaching children with autism spectrum disorders and other disabilities. The project evaluates a package to train teachers to use software called the Pivotal Skills Trainer and examines whether doing so improves preschoolers' functional communic ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Autism Education and Treatment with PowerPoint Software

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): PowerPoint(R) multimedia software is ubiquitous in our schools but its capacity for teaching children with autism spectrum and related disorders barely has been realized. This STTR (Phase I) project will begin to change this state of affairs by researching and developing empirically derived multimedia teaching tools. Encouraged by early-stage feasibility work, ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Inhibitors of Pim Protein Kinases

    SBC: Vortex Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. HT-production of Abs using Interaction Trap in Yeast

    SBC: AFFOMIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Affomix would like to commercialize antibody chips to enable researchers to study the human proteome. Currently, researchers use gene chips as a surrogate means to estimate the concentration of the vast variety of pro teins in cells and tissues. But given the choice, most researchers would prefer to study the proteins directly because of the; i) poor correla ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Snapshot Raman Spectral Imager

    SBC: Applied Quantum Technologies            Topic: A09AT009

    Applied Quantum Technologies along with its university partner Duke University propose a coded-aperture, multi-aperture snapshot Raman imager. By combining an innovative optical design and advanced compressed sensing algorithms, a snapshot system provides dwell times much shorter than conventional slit-based or tunable-filter based spectral imagers. A short-wave infrared excitation source allows f ...

    STTR Phase I 2009 Department of DefenseDefense Advanced Research Projects Agency
  6. NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

    SBC: ARGOLYN BIOSCIENCE, INC.            Topic: N/A

    Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

    SBC: ARGOLYN BIOSCIENCE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric antipsychotics expected not to display the adverse side effects associated with the dopaminergics. The best lit ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. USING AL TO ENHANCE VR ANXIETY DISORDER TREATMENT

    SBC: ARGUS VR INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant) This project will develop an artificial intelligence to provide the core functionality for virtual reality and computer based treatments for anxiety disorders. The use of artificial intelligence offers a number of advantages over existing treatments: (1) artificial intelligence provides personalized treatment - using multiple real time physiologic and subjective ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. Huperzine for Cognitive and Functional Impairment in Schizophrenia

    SBC: BIOMEDISYN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Schizophrenia affects approximately 3 million people in the US, and it is one of the leading causes of disability. Currently available drugs are only partially effective, particularly for the cognitive impairments that contribute to functional loss. A new investigational drug, BMD-101, has been shown to have neuroprotective, neurotrophic, cholinergic, and dopa ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. DEVELOPMENT OF A NEW TREATMENT OF URINARY STONE DISEASE

    SBC: BIOSTRATUM, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new method for prophylaxis and treatment of urinary stone disease is proposed. Since a majority of urinary stones are made of calcium oxalate, the level of urinary oxalate is one of the major risk factors of stone formation. Unfortunately, there is no effective pharmacological treatment of stone disease that targets urinary oxalate concentratio ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government